A new study published in MedComm demonstrates that Nicotinamide Mononucleotide (NMN) supplementation can significantly reverse age-associated changes in oocyte quality and ovarian function in mice. The research, highlighted by prominent aging researcher David Sinclair in a recent tweet, offers promising insights into potential strategies for addressing age-related female infertility.
The study, titled "Nicotinamide mononucleotide supplementation rescues mitochondrial and energy metabolism functions and ameliorates inflammatory states in the ovaries of aging mice," found that NMN effectively restored ovarian nicotinamide adenine dinucleotide (NAD+) levels, which typically decline with age. This restoration led to a notable improvement in the quality and quantity of ovulated oocytes in aged mice, alongside the inhibition of ovarian atrophy and enhanced hormone secretion. Specifically, NMN treatment notably increased the number of ovulated oocytes and reduced morphological defects in them.
Researchers observed that NMN's beneficial effects are mediated through enhanced mitochondrial function, improved energy metabolism, and reduced inflammation within the ovaries. Transcriptomic analysis revealed that NMN treatment upregulated genes associated with energy-related metabolic pathways while downregulating those linked to inflammation and immunity. These molecular changes contributed to an increase in the number of ovarian follicles at various developmental stages, effectively slowing the decline in ovarian reserves.
The findings suggest NMN could offer a noninvasive pharmacological strategy to combat age-related ovarian infertility. While the current research was conducted on mice, another related study also indicated that in vitro NMN supplementation improved the nuclear competence of immature human oocytes from women of advanced maternal age, boosting the rescue rate by 25%. Such advancements could have significant implications for assisted reproductive technologies (ART) and the broader field of anti-aging research.
David Sinclair, a leading figure in aging research, drew attention to the study's accessibility, stating in his tweet, "> The actual paper @ journal of reproductive development - free to download: https://t.co/nX25dZB4wr." The open-access nature of the publication ensures wider dissemination of these critical findings. Further research is needed to validate these effects in human clinical trials and to fully understand the long-term impact and optimal application of NMN for reproductive health.
